Cost-effectiveness Analysis of CYP2D6*10 Pharmacogenetic Testing to Guide the Adjuvant Endocrine Therapy for Postmenopausal Women with Estrogen Receptor Positive Early Breast Cancer in China

  • 43 Accesses

  • 1 Citations



A CYP2D6 gene polymorphism is related to the effect of tamoxifen treatment in patient with estrogen-receptor positive (ER) positive breast cancer and CYP2D6*10 T/T can lead to a poor prognosis in Asian patients. Although one-off pharmacogenetic testing may optimize adjuvant endocrine therapy, testing prior to tamoxifen initiation incurs additional costs.


We conducted a study to assess the cost-effectiveness of CYP2D6*10 pharmacogenetic testing to guide the adjuvant endocrine therapy compared with tamoxifen without CYP2D6*10 testing in China.


A semi-Markov model was developed to evaluate costs and health outcomes represented as quality adjusted life year (QALY) gained. Input data were obtained from the public literature. The results were expressed as incremental cost per QALY gained. A one-way deterministic sensitivity analysis explored the impact of uncertainty in the model parameters on results, and probabilistic uncertainty was assessed through a Monte Carlo probabilistic sensitivity analysis.


In the base-case analysis, in the CYP2D6*10 testing and alternative adjuvant endocrine therapy group, the incremental total cost was US$17,966.95 and the incremental QALY was 3.582. Thus, the incremental cost-effectiveness ratio was US$5015.693 per QALY gained. Compared with a willingness-to-pay threshold of US$26,508/QALY in China, the CYP2D6*10 testing is the dominant strategy in postmenopausal women with ER-positive breast cancer in China, and the increased cost of genetic testing was completely worthwhile. The sensitivity analyses showed that the model we built was quite stable.


From the perspective of the Chinese healthcare system, CYP2D6*10 pharmacogenetic testing was cost effective for postmenopausal women with ER-positive early breast cancer.

This is a preview of subscription content, log in to check access.

Access options

Buy single article

Instant unlimited access to the full article PDF.

US$ 49.95

Price includes VAT for USA

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5


  1. 1.

    Kristyanto H, Utomo AR. Pharmacogenetic application in personalized cancer treatment. Acta Med Indones. 2010;42(2):109–15.

  2. 2.

    Klein ME, Parvez MM, Shin JG. Clinical implementation of pharmacogenomics for personalized precision medicine: barriers and solutions. J Pharm Sci. 2017;106(9):2368–79.

  3. 3.

    Ji Y, Skierka JM, Blommel JH, Moore BE, VanCuyk DL, Bruflat JK, et al. Preemptive pharmacogenomic testing for precision medicine: a comprehensive analysis of five actionable pharmacogenomic genes using next-generation dna sequencing and a customized CYP2D6 genotyping cascade. J Mol Diagn. 2016;18(3):438–45.

  4. 4.

    Verbelen M, Weale ME, Lewis CM. Cost-effectiveness of pharmacogenetic-guided treatment: are we there yet? Pharmacogenomics J. 2017;17(5):395–402.

  5. 5.

    McGraw J, Waller D. Cytochrome P450 variations in different ethnicpopulations. Expert Opin Drug Metab Toxicol. 2012;8(3):371–82.

  6. 6.

    Hertz DL, Rae JM. One step at a time: CYP2D6 guided tamoxifen treatment awaits convincing evidence of clinical validity. Pharmacogenomics. 2016;17(8):823–6.

  7. 7.

    Kiyotani K, Mushiroda T, Nakamura Y, Zembutsu H. Pharmacogenomics of tamoxifen: roles of drug metabolizing enzymes and transporters. Drug Metab Pharmacokinet. 2012;27(1):122–31.

  8. 8.

    Goetz MP, Sangkuhl K, Guchelaar HJ, Schwab M, Province M, Whirl-Carrillo M, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 and tamoxifen therapy. Clin Pharmacol Ther. 2018;103(5):770–7.

  9. 9.

    Ozawa S, Soyama A, Saeki M, Fukushima-Uesaka H, Itoda M, Koyano S, et al. Ethnic differences in genetic polymorphisms of CYP2D6, CYP2C19, CYP3As and MDR1/ABCB1. Drug Metab Pharmacokinet. 2004;19(2):83–95.

  10. 10.

    Lin G, Zhang K, Yi L, Han Y, Xie J, Li J. National prociency testing result of CYP2D6*10 genotyping for adjuvant tamoxifen therapy in China. PLoS One. 2016;11(9):e0162361.

  11. 11.

    Park GC, Jung JA, Bae KS, Lim HS. A simulation study to compare the treatment effect of tamoxifen by CYP2D6 genotypes and third-generation aromatase inhibitors. J Clin Pharmacol. 2017;57(9):1088–96.

  12. 12.

    Lu J, Li H, Guo P, Shen R, Luo Y, Ge Q, et al. The effect of CYP2D6*10 polymorphism on adjuvant tamoxifen in Asian breast cancer patients: a meta-analysis. Onco Targets Ther. 2017;10:5429–37.

  13. 13.

    Bai Y, Wu HW, Zhang YH. Effects of CYP2D6*10 polymorphism on tamoxifen pharmacokinetics in patients with breast cancer in Asia: a meta-analysis. Cancer Chemother Pharmacol. 2019;83(1):71–9.

  14. 14.

    Prina AM, Wu YT, Kralj C, Acosta D, Acosta I, Guerra M, et al. Dependence- and disability-free life expectancy across eight low- and middle-income countries: a 10/66 study. J Aging Health; 2019: 898264319825767.

  15. 15.

    Lan B, Ma F, Zhai X, et al. The relationship between the CYP2D6 polymorphisms and tamoxifen efficacy in adjuvant endocrine therapy of breast cancer patients in Chinese Han population. Int J Cancer. 2018;143(1):184–9.

  16. 16.

    Regan MM, Leyland-Jones B, Bouzyk M, Pagani O, Tang W, Kammler R, Breast International Group (BIG) 1-98 Collaborative Group, et al. CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial. J Natl Cancer Inst. 2012;104(6):441–51.

  17. 17.

    Kimura M, Tominaga T, Kimijima I, et al. Phase III randomized trial of toremifene versus tamoxifen for Japanese postmenopausal patients with early breast cancer. Breast Cancer. 2014;21(3):275–83.

  18. 18.

    Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet. 2015;386(10001):1341–52.

  19. 19.

    van de Velde CJ, Rea D, Seynaeve C, et al. Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial. Lancet. 2011;377(9762):321–31.

  20. 20.

    Zhang X. Association of CYP2D6*10, OATP1B1 polymorphisms and therapeutic effects of breast cancer patients after tamoxifen therapy, M.M. Thesis, Wan Nan Medical College; 2017. p. 28.

  21. 21.

    ISPOR. Pharmacoeconomic guidelines around the world [EB/OL] [2016-07-30].

  22. 22.

    Sang GW, Liu GE, Hu SL, Wu JH, Wu J, Yang L, et al. China guidelines for pharmacoeconomic evaluations and manual. Beijing: Science Press; 2015.

  23. 23.

    Li S, Legood R, Li Y. Economic evaluation of ultrasonography and mammography for breast cancer screening among women in China. Chin J Health Policy. 2017;10(04):42–50.

  24. 24.

    Van Nuland M, Vreman RA, Ten Ham RMT, et al. Cost-effectiveness of monitoring endoxifen levels in breast cancer patients adjuvantly treated with tamoxifen. Breast Cancer Res Treat. 2018;172(1):143–50.

  25. 25.

    Varier RU, Biltaji E, Smith KJ, et al. Cost-effectiveness analysis of fecal microbiota transplantation for recurrent Clostridium difficile infection. Infect Control Hosp Epidemiol. 2015;36(4):438–44.

  26. 26.

    List of Chinese administrative divisions by GDP per capita. Accessed 23 Apr 2018.

  27. 27.

    Fan L, Strasser-Weippl K, Li JJ, St Louis J, Finkelstein DM, Yu KD, et al. Breast cancer in China. Lancet Oncol. 2014;15(7):e279–89.

  28. 28.

    Wu JH, Wu J, Zhao YL, et al. Pharmacoeconomics. Beijing: Higher Education Press; 2017.

  29. 29.

    Woods B, Veenstra D, Hawkins N. Prioritizing pharmacogenetic research: a value of information analysis of CYP2D6 testing to guide breast cancer treatment. Value Health. 2011;14(8):989–1001.

  30. 30.

    Zhu K, Zhang L, Yuan S, Zhang X, Zhang Z. Health financing and integration of urban and rural residents’ basic medical insurance systems in China. Int J Equity Health. 2017;16(1):194.

Download references

Author information

Correspondence to Jiaqin Cai.

Ethics declarations


This study was supported in part by grants from the Natural Science Foundation of Fujian (No. 2019J01177), high-level hospital foster grants from Fujian Provincial Hospital (No. 2019HSJJ06), Fujian Science and Technology Innovation Joint Fund Project (No. 2017Y9067), Startup Fund for scientific research, Fujian Medical University (No. 2016QH106 and No. 2016QH107), Youth Scientific Research Project of Fujian Provincial Health Department (No. 2016-1-8) and the Science and Technology, Department of Fujian Province (No. 2018R0041) of the People’s Republic of China.

Conflict of interest

The authors declare that they have no conflicts of interest to disclose regarding this study. All the authors were substantially involved in the study and/or preparation of the manuscript. All authors declare no support from any organization for the submitted work; All authors declare no other relationships or activities that could appear to have influenced the submitted work. The present study was not supported by a pharmaceutical company, and no persons or entity had input into the design or analysis of the cost-effective analysis besides the listed authors.

Ethical approval

This article does not contain any studies with human participants performed by any of the authors.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Wei, X., Sun, H., Zhuang, J. et al. Cost-effectiveness Analysis of CYP2D6*10 Pharmacogenetic Testing to Guide the Adjuvant Endocrine Therapy for Postmenopausal Women with Estrogen Receptor Positive Early Breast Cancer in China. Clin Drug Investig 40, 25–32 (2020) doi:10.1007/s40261-019-00842-0

Download citation